Prophylaxis of invasive mycoses in solid organ transplantation

Current Opinion in Infectious Diseases

Volumn 15, Issue 6, 2002, Pages 583-589

  Alexander, Barbara D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fungal infections; Mycoses; Organ transplantation; Prophylaxis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; OKT 3; PLACEBO; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; BRONCHOSPASM; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICAL NEBULIZER; MULTICENTER STUDY; MYCOSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SURGICAL PATIENT; THROMBOCYTOPENIA; VOMITING;

EID: 0036915448     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200212000-00005     Document Type: Review

References (69)

1. Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14:375-382.
2. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-688.
3. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11:291-308.
4. Kramer MR, Marshall SE, Starnes VA, et al. Infectious complications in heart-lung transplantation: Analysis of 200 episodes. Arch Intern Med 1993; 153:2010-2016.
5. Maurer JR, Tullis DE, Grossman RF, et al. Infectious complications following isolated lung transplantation. Chest 1992; 101:1056-1059.
6. Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8:207-215.
7. Singh N. Antifungal prophylaxis for solid organ transplant recipients: Seeking clarity amidst controversy. Clin Infect Dis 2000; 31:545-553.
8. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106-113.
9. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001; 3:203-211. A retrospective analysis of the renal transplant registry (1994-1997) documented that end-stage renal disease due to diabetes and duration of pretransplant dialysis, in addition to maintenance tacrolimus and allograft rejection, were associated with development of IFIs.
10. Singh N, Avery RK, Munoz P, et al. Trends in risk-profiles and mortality due to invasive aspergillosis in liver transplant recipients. Clin Infect Dis (in press). Documents significant trends in the epidemiology and outcome of aspergillosis in OLT. In particular, the majority of Aspergillus infections are now occurring after 90 days following transplantation rather than in the first 3 months after transplant.
11. Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59:851-859.
12. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644-652.
13. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126:149-156.
14. Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14:375-382.
15. Karchmer AW, Pappas P, Merion R, et al. Invasive fungal infections in liver transplant recipients (LTR) considered at low risk [abstract]. In; Progam and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America; 24-27 October 2002; Chicago, IL.
16. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices, Transplantation 2002; 73:63-67. Documents notable technical developments in OLT practices over the past decade. These developments have resulted in significant changes in risk profiles for IFIs in this population following transplantation.
17. Kubak BM, Pegues DA, Holt CD, Hwang AH. Changing patterns of fungal infection in transplantation. Curr Opin Organ Transpl 2000; 5:176-191.
18. Singh N, Linden P, Munoz P, Dominguez E. Emerging trends in invasive mould infections in organ transplant recipients [abstract]. In: Progam and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2000; Toronto, Canada. Washington, DC: American Society for Microbiology; 2000. Abstract 1327.
19. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917.
20. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mould infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-1324.
21. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62:926-934.
22. Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166:1379-1383.
23. Rogers J, Rohal S, Carrigan DR, et al. Human herpesvirus-6 in liver transplant recipients: Role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69:2566-2573.
24. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64:716-720.
25. Singh N, Paterson DL, Gayowski T, et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71:910-913.
26. Ankersmit HJ, Deicher R, Moser B, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 2001; 125:142-148. Renal failure and initiation of hemodialysis were shown to result in a reduced proliferative T-cell response and an aberrant state of T-cell activation resulting in a heightened susceptibility to activation-induced cell death. This may lead to increase susceptibility to opportunistic infections.
27. Chang FY, Singh N, Gayowski T, et al. Thrombocytopenia in liver transplant recipients: Predictors, impact on fungal infections, and role of endogenous thrombopoietin. Transplantation 2000; 69:70-75.
28. Christin L, Wysong DR, Meshulam T, et al. Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils. Infect Immun 1998; 66:1181-1189.
29. Yeldandi V, Laghi F, McCabe MA, et al. Aspergillus and lung transplantation. J Heart Lung Transpl 1995; 14:883-890.
30. Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995; 60:1473-1477.
31. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999; 67:399-403.
32. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26:753-755.
33. Paradowski LJ. Saprophytic fungal infections and lung transplantation: Revisited. J Heart Lung Transpl 1997; 16:524-531.
34. Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: Case series and review of the literature. Chest 2001; 119:169-175.
35. Westney GE, Kesten S, de Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61:915-919.
36. Malani PN, Dyke DB, Pagani FD, Chenoweth CE. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis 2002; 34:1295-1300.
37. Ankersmit HJ, Tugulea S, Spanier T, et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 1999; 354:550-555.
38. Ankersmit HJ, Moser B, Hoffman M, et al. Aberrant T-cell activation via CD95 and apoptosis in peripheral T lymphocytes in stable heart transplant recipients. Transpl Proc 2001; 33:2860-2861. VAD placement results in an aberrant state of T-cell activation, higher surface expression of CD95, and a higher rate of spontaneous apoptosis. Authors speculate this to be a mechanism for increased susceptibility to opportunistic infections such as Candida.
39. Burket JS, Bartlett RH, Vander HK, Chenoweth CE. Nosocomial infections in adult patients undergoing extracorporeal membrane oxygenation. Clin Infect Dis 1999; 28:828-833.
40. O'Neill JM, Schutze GE, Heulitt MJ, et al. Nosocomial infections during extracorporeal membrane oxygenation. Intensive Care Med 2001; 27:1247-1253.
41. Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174:583-588.
42. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729-737.
43. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients. Medicine 1998; 77:246-254.
44. Kung N, Fisher N, Gunson B, et al. Fluconazole prophylaxis for high-risk liver transplant recipients [letter; comment]. Lancet 1995; 345:1234-1235.
45. Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mould infections in immunosuppressed hosts: An alternative hypothesis [letter; comment]. Clin Infect Dis 2002; 34:1281-1283 [erratum in Clin Infect Dis 2002; 35:110].
46. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
47. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-316.
48. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-1277.
49. Safdar A, van Rhee F, Henslee-Downey JP, et al. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: No adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transpl 2001; 28:873-878.
50. Montoya A. Efficacy of itraconazole prophylaxis for aspergillosis in lung transplant recipients [abstract]. In: Program and Abstracts of the 32nd Annual Meeting of the Infectious Diseases Society of America; New Orleans, LA; 1994. Abstract P58A.
51. Munoz P, Palomo J, Yanes J, et al, Primary prophylaxis with itraconazole of invasive aspergillosis (IA) in heart transplant (HT) patients [abstract], In: Program and Abstracts of the 39th Interscience Conference on Anitmicrobial Agents and Chemotherapy; 26-29 September 1999; San Francisco, CA; Washington, DC: American Society for Microbiology; 1999, Abstract 1416.
52. Colby WD, Sharpe MD, Ghent CN. Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients [abstract]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 26-29 September 1999; San Francisco, CA. Washington, DC: American Society for Microbiology; 1999. Abstract 1650.
53. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: Association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin Infect Dis 1993; 17:906-908.
54. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transpl 2000; 25:853-859.
55. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891-897.
56. Varo E, Tome S, Bustamante M, et al. Fungal infection prophylaxis in high-risk liver transplant recipients [abstract]. In: Programs and Abstracts of the 38th International Conference on Antimicrobial Agents and Chemotherapy; 24-27 September 1998; San Diego, CA. Washington, DC: American Society for Microbiology; 1998. p. 490.
57. Lorf T, Braun F, Ruchel R, et al. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999; 42:47-53.
58. Tollemar J, Hockerstedt K, Ericzon BG, et al. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: A randomized, placebo-controlled study. Transplantation 1995; 59:45-50.
59. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transpl Proc 1997; 29:627-628.
60. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72:545-548. First pilot study documenting the safety and tolerability of aerosolized amphotericin B lipid complex as prophylaxis for aspergillosis after lung transplantation.
61. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-571.
62. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-234. Large, randomized multicenter trial of voriconazole versus ambisome for empiric therapy of febrile neutropenia. Fewer breakthrough infections in the voriconazole arm.
63. Groll AH, Walsh TJ. Caspofungin: Pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Invest Drugs 2001; 10:1545-1558.
64. Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: A multicenter, randomized, double-blind study [abstract]. In: Abstracts of the 12th European Congress of Microbiology and Infectious Diseases; 2002; Milan, Italy. Taufkirchen, Germany: European Society of Clinical Microbiology; 2002. Abstract F37.
65. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14:685-691.
66. Barchiesi F, Schimizzi AM, Fothergill AW, et al. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999; 18:302-304.
67. Holman WL, Murrah CP, Ferguson ER, et al. Infections during extended circulatory support: University of Alabama at Birmingham experience 1989 to 1994. Ann Thorac Surg 1996; 61:366-371.
68. Holman WL, Skinner JL, Waites KB, et al. Infection during circulatory support with ventricular assist devices. Ann Thorac Surg 1999; 68:711-716.
69. Singh N. Antifungal prophylaxis for solid organ transplant recipients: Seeking clarity amidst controversy. Clin Infect Dis 2000; 31:545-553.